Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

<b>Background/Objectives:</b> Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D), obesity, and liver fibrosis (resmetirom) announce the widespread use of fibrosis tests in patients with metabolic liver disease (MASLD). An unmet need is to reduce the uncertainty of biomarker...

Full description

Saved in:
Bibliographic Details
Main Authors: Thierry Poynard, Olivier Deckmyn, Raluca Pais, Judith Aron-Wisnewsky, Valentina Peta, Pierre Bedossa, Frederic Charlotte, Maharajah Ponnaiah, Jean-Michel Siksik, Laurent Genser, Karine Clement, Gilles Leanour, Dominique Valla
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Diagnostics
Subjects:
uncertainty
Obuchowski measure
early liver fibrosis
granularity
UK BioBank
biopsy length
Online Access:https://www.mdpi.com/2075-4418/15/10/1253
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2075-4418/15/10/1253

Similar Items